Scarica l'app Stockscreener
33.50
0.30%
0.10
Dopo l'orario di chiusura:
33.80
0.30
+0.90%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VKTX Giù?
Forum
Previsione
Precedente Chiudi:
$33.40
Aprire:
$31.5
Volume 24 ore:
7.80M
Relative Volume:
2.18
Capitalizzazione di mercato:
$3.76B
Reddito:
-
Utile/perdita netta:
$-99.15M
Rapporto P/E:
-36.02
EPS:
-0.93
Flusso di cassa netto:
$-74.25M
1 W Prestazione:
+4.46%
1M Prestazione:
+24.30%
6M Prestazione:
-2.90%
1 anno Prestazione:
-33.54%
Intervallo 1D:
$31.22
$34.67
Intervallo di 1 settimana:
$31.22
$34.67
Portata 52W:
$18.92
$81.73
Viking Therapeutics Inc Stock (VKTX) Company Profile
Nome
Viking Therapeutics Inc
Settore
Industria
Telefono
858-704-4660
Indirizzo
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
Confronta VKTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
33.50 | 3.75B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-29 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-04-08 | Iniziato | Goldman | Neutral |
| 2025-02-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-02-07 | Iniziato | Citigroup | Neutral |
| 2024-12-02 | Iniziato | Piper Sandler | Overweight |
| 2024-11-22 | Iniziato | B. Riley Securities | Buy |
| 2024-11-04 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-11 | Iniziato | JP Morgan | Overweight |
| 2024-06-27 | Iniziato | Morgan Stanley | Overweight |
| 2024-05-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | Reiterato | Oppenheimer | Outperform |
| 2024-03-07 | Iniziato | Jefferies | Buy |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2023-05-31 | Ripresa | ROTH MKM | Buy |
| 2023-03-28 | Reiterato | Maxim Group | Buy |
| 2023-03-17 | Iniziato | Stifel | Buy |
| 2021-07-29 | Ripresa | BTIG Research | Buy |
| 2021-05-25 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | Iniziato | BMO Capital Markets | Outperform |
| 2020-05-05 | Iniziato | Chardan Capital Markets | Buy |
| 2020-05-01 | Iniziato | BTIG Research | Buy |
| 2019-07-16 | Iniziato | Oppenheimer | Outperform |
| 2019-06-25 | Iniziato | Stifel | Buy |
| 2019-03-29 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | Reiterato | Maxim Group | Buy |
| 2019-02-22 | Iniziato | SVB Leerink | Mkt Perform |
| 2018-12-12 | Iniziato | B. Riley FBR | Buy |
| 2018-11-19 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-18 | Reiterato | Maxim Group | Buy |
| 2018-09-18 | Reiterato | Raymond James | Outperform |
| 2018-07-20 | Iniziato | SunTrust | Buy |
| 2018-06-28 | Iniziato | Raymond James | Outperform |
| 2018-06-01 | Reiterato | Laidlaw | Buy |
| 2018-05-31 | Reiterato | Maxim Group | Buy |
| 2018-03-26 | Ripresa | H.C. Wainwright | Buy |
| 2017-11-28 | Reiterato | Maxim Group | Buy |
| 2017-11-21 | Iniziato | ROTH Capital | Buy |
Mostra tutto
Viking Therapeutics Inc Borsa (VKTX) Ultime notizie
Viking Therapeutics’ Earnings Call: Clinical Advances Amid Financial Challenges - TipRanks
Viking Therapeutics EPS miss sends shares down 7% - MSN
Viking Therapeutics Inc. Stock Analysis and ForecastBreakthrough wealth creation - PrintWeekIndia
Viking Therapeutics Q2 Earnings Miss Estimates, R&D Expenses Rise - AInvest
VKTX Stock Down on Wider-Than-Expected Loss in Q2, Nil Sales - Nasdaq
Viking Therapeutics stock rating reiterated by Cantor Fitzgerald at $104 - Investing.com
Viking Therapeutics, Inc. (VKTX): A Bull Case Theory - Insider Monkey
Viking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: Navigating Increased R&D ... - Yahoo Finance
Is Viking Therapeutics Inc. a good long term investmentPhenomenal capital appreciation - jammulinksnews.com
Viking Therapeutics Inc (VKTX) Q2 2025 Earnings Call Highlights: - GuruFocus
Viking Therapeutics Advances Clinical Pipeline Amid Financial Losses - TipRanks
Viking Therapeutics' Q2 2025 Earnings Call: Unpacking Key Contradictions in Phase III Study Strategy - AInvest
Viking Therapeutics Posts Wider Q2 Loss - AOL.com
Viking Therapeutics EPS miss sends shares down 7% (VKTX:NASDAQ) - Seeking Alpha
Viking Therapeutics Stock Slides After Company Misses Q2 Earnings Estimates - Benzinga
Viking Therapeutics, Inc. SEC 10-Q Report - TradingView
Viking Therapeutics shares fall as Q2 loss exceeds estimates By Investing.com - Investing.com India
Viking (VKTX) Q2 2025 Earnings Call Transcript - Mitrade
Viking Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update | VKTX Stock News - GuruFocus
Viking Therapeutics Advances Dual Obesity Drug Strategy: Injectable Phase 3 Trials Begin as Oral Version Nears Data - Stock Titan
What analysts say about Viking Therapeutics Inc. stockSuperior stock selection - jammulinksnews.com
Viking Therapeutics (VKTX) Options Activity Surges Ahead of Earnings | VKTX Stock News - GuruFocus
Viking Therapeutics to Report Q2 2025 Financial Results on July 23, 2025 - AInvest
Viking Therapeutics, Inc. (NASDAQ:VKTX) institutional owners may be pleased with recent gains after 38% loss over the past year - Yahoo Finance
Viking Therapeutics to Report Financial Results for Second Quarter 2025 on July 23, 2025 - Finansavisen
What drives Viking Therapeutics Inc. stock priceHigh-profit trading signals - jammulinksnews.com
Viking Therapeutics (VKTX) Set to Release Q2 Earnings Results - GuruFocus
Better Growth Buy: Eli Lilly vs. Viking Therapeutics - Mitrade
Viking Therapeutics Gears Up for Q2 Earnings: Here's What to Expect - Yahoo Finance
Is It Worth Investing in Viking Therapeutics (VKTX) Based on Wall Street's Bullish Views? - MSN
3 Monster Stocks in the Making to Buy Right Now - The Motley Fool
Viking Therapeutics VKTX 2025Q2 Earnings Preview Upside Potential Driven by Analyst Price Targets - AInvest
Viking Therapeutics (VKTX) Soars 9.7% on Looming Weight Loss Drug Trial Results - MSN
(VKTX) On The My Stocks Page - news.stocktradersdaily.com
Viking Therapeutics (VKTX) Soars 3.40% on Bullish Analyst Sentiment - AInvest
Viking Therapeutics Inc Azioni (VKTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.32%
1.57%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):